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Glutathione S‑transferase homozygous deletions and 
relapse in childhood acute lymphoblastic leukemia: 
a novel study design in a large Italian AIEOP cohort
Nowadays, more than 80% of pediatric patients 
affected by acute lymphoblastic leukemia (ALL) 
become long‑term cancer survivors and healthy 
adults [1–3]. Despite continuous advances in 
survival rates during the past 50 years, due to 
the successful risk‑adapted polychemotherapy, 
relapse remains the main cause of treatment 
failure, with salvage therapy being still associated 
with unsatisfactory outcome [4]. Choice of 
optimal intensity of front‑line therapy, by 
promptly employing more aggressive regimens 
in patients with less‑responsive disease, and by 
reducing intensity of treatment and the related 
toxicity in responsive patients, is considered the 
best approach to optimize a patient’s outcome. 
ALL is a heterogeneous disease, having many 
subtypes characterized by genetic alterations in 
the leukemic cells of patients’ whose prognostic 
values are generally known (i.e., unfavorable 
chromosomal translocations t[9;22] and t[4;11]) 
and considered for treatment risk stratification. 
On the contrary, patients’ polymorphisms in 
genes influencing drug disposition, metabolism 
and mechanisms of action are generally not taken 
into account in current clinical protocols, with 
the exception of thiopurine S‑methyltransferase 
variants used for modulating 6‑mercaptopurine 
dosage. Such genetic features might affect 
treatment efficacy and could therefore be 
promising candidates to better assess the risk 
of each patient and to personalize therapy [5,6].
Glutathione S ‑transferases (GSTs) are 
phase II enzymes that catalyze the conjugation of 
electrophilic compounds to glutathione (GSH), 
thus producing water‑soluble compounds that 
are more easily excreted via the kidneys. As 
metabolizing enzymes, they detoxify a wide 
range of drugs, including those normally 
employed in chemotherapy regimens [7–13]. 
Furthermore, GSTs sequester alkylating agents 
and steroids by direct binding [14] and also act 
as cell‑signaling modulators by protein–protein 
interactions. In particular, GST‑P1 and GST‑M1 
are negative regulators of proapoptotic signaling 
pathways. Overexpression of GST proteins and 
high levels of GSH have been associated with 
the development of drug resistance in a variety 
of cell lines and tumor tissues, [15,16] probably 
as a consequence of enhanced metabolism and 
decreased bioavailability of anticancer agents, as 
well as of impairment of the apoptotic process 
in malignant cells.
Aim: In the AIEOP-BFM 2000 trial, 15% of pediatric patients treated according to risk-adapted 
polychemotherapeutic regimens relapsed. The present study aimed to investigate the influence of GST‑M1 
and GST‑T1 deletions on clinical outcome of children with acute lymphoblastic leukemia treated according 
to the AIEOP-BFM ALL 2000 study protocol. Materials & methods: A novel-design, two-phase study was 
applied to select a subsample of 614 children to be genotyped for the deletions of GST genes. Cumulative 
incidence of relapse was then estimated by weighted Kaplan–Meier analysis, and the Cox model was 
applied to evaluate the effect of GST‑M1 and GST‑T1 isoenzyme deletions on relapse. Results: No overall 
effect was found, but the GST‑M1 deletion was associated with better clinical outcome within prednisone 
poor-responder patients (hazard ratio [HR]: 0.45; 95% CI: 0.23–0.91; p = 0.026), whereas the GST‑T1 
deletion was associated with worse outcome in the standard-risk group (HR: 4.62; 95% CI: 1.04–20.6; 
p = 0.045) and within prednisone good responders (HR: 1.62; 95% CI: 1.02–2.58; p = 0.041). Conclusion: 
Our results show that GST‑M1 and GST‑T1 homozygous deletions have opposite correlation with relapse, 
the former being protective and the latter unfavourable in specific subsets of acute lymphoblastic leukemia 
patients.
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GST‑M1 and GST‑T1 exhibit a genetic 
polymorphism in Caucasians, with 42–60 
and 13–26% of individuals displaying 
a homozygous deletion of the gene (null 
genotype), respectively. Subjects carrying the 
null variants fail to express the corresponding 
proteins [17,18]. GST‑M1 and GST‑T1 deletions 
were previously proposed as candidates for 
disease susceptibility and as variables influencing 
clinical outcome in childhood ALL, although 
controversial/conf licting results have been 
reported [19–24].
Pharmacogenomic research is challenged 
by the need to investigate large cohorts but, 
when precious biological samples from data 
banks need to be analyzed, resources might be 
limited for data ascertainment on all subjects. 
For this reason, we propose a two‑phase design 
that allows the study of information available 
from large cohorts (known as the first phase) 
and also information available only on a selected 
subset (the second phase) of the same cohort at 
the same time. The design optimizes the choice 
of the subcohort to be genotyped in order to 
acquire efficient estimates [25].
In this study, we propose a two‑phase 
pharmacogenetic design to investigate the 
influence of GST‑M1 and GST‑T1 deletions on 
clinical outcome in the large cohort of children 
with ALL treated according to the AIEOP‑BFM 
ALL 2000 study protocol.
Materials & methods
n Study population
Patients
This study was based on 1999 consecutive 
patients (mainly European Caucasians, aged 
between 1 and 18 years, median age: 5 years) 
who were newly diagnosed with Philadelphia 
chromosome–negative ALL in Italian AIEOP 
centers between September 2000 and July 
2006. Within this cohort, 1113 patients were 
males (55.7%). The majority of patients were 
preschool children (age less than 6 years; 
59.6%), while 402 (20.1%) were older than 
10 years of age. Patients were treated according 
to the AIEOP‑BFM ALL 2000 study protocol 
(ClinicalTrials.gov identifier NCT00613457 
[101]). Based on minimal residual disease (MRD) 
levels, response to the first week of steroids, 
resistance to induction therapy and presence of 
chromosomal translocations t(4;11) and t(9;22) 
[26], patients were divided into standard‑ (515; 
25.76%), medium‑ (1173; 58.68%) and high‑
risk groups (311; 15.56%), and treated with risk‑
adjusted polychemotherapeutic regimens [27]. 
Overall, 306 patients relapsed (15.3%), 28 in 
the standard‑, 186 in the medium‑ and 92 in 
the high‑risk group (Table 1). Written informed 
consent was obtained from the parents or legal 
guardians before patient enrolment, while the 
protocol was approved by the ethics committee 
of each participating institution.
Study design
This work adopts a novel approach, known as 
two‑phase design, for both the selection of the 
subsample to be genotyped and the statistical 
ana lysis for the correlation between genotype 
and clinical outcome [25,28,29].
In principle, the design selects for genotyping 
patients of the AIEOP‑BFM ALL 2000 trial, 
along the following optimal sampling fractions: 
first, 100% of the patients who relapsed by April 
2008 (306 cases); and second, 13, 26 and 64% 
of nonrelapsed patients randomly chosen within 
the standard‑, medium‑ and high‑risk groups, 
respectively, for a total subset of 460 patients 
in remission. These optimal sampling fractions 
have been set on the basis of a pilot study on 
164 genotyped patients and vary proportionally 
to the genetic variability reported within each of 
the risk groups, thus maximizing the precision of 
the estimate of the genotype effect on outcome. 
Because of this optimization, the subcohort is 
not representative of the entire cohort and thus 
Table 1. Sampled genotyped subgroup with respect to the whole cohort of 
1999 acute lymphoblastic leukemia patients enrolled in the AIEOP‑BFM ALL 2000 
study protocol, classified according to relapse and risk group.
Relapse Risk group: genotyped subgroup (n)/ 
whole cohort (n), (%)
Total cohort: genotyped 
subgroup (n)/whole 
cohort (n), (%)Standard Medium High
No 56/487 (11.5) 196/987 (19.9) 111/219 (50.7) 363/1693 (21.4)
Yes 22/28 (78.6) 149/186 (80.1) 80/92 (87.0) 251/306 (82.0)
Total 78/515 (15.1) 345/1173 (29.4) 191/311 (61.4) 614/1999 (30.7)
The percentage of effective sampling fraction in each stratum is reported in brackets.
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the method subsequently adopted for statistical 
ana lysis introduces appropriate weights in order 
to recover the representativeness of the subsample 
[25,28,29]. The optimal sampling fractions have 
been computed using the software developed by 
Reilly and Salim available from the Karolinska 
Institutet, Stockholm, Sweden [102]. Software 
for mean score ana lysis and optimal design of 
two‑phase studies was written in R (R cran, R 
Foundation for Statistical Computing, Vienna, 
Austria), SPLUS (Insightful Corp., WA, USA) 
and STATA (StataCorp LP, TX, USA).
Overall, out of the 766 children for whom 
genotyping was required, stored DNA material 
was available for 251 relapsed individuals and 
for 363 patients in remission. Table 1 reports the 
distribution of genotyped patients in comparison 
with the whole cohort and the effective sampling 
fractions used in each stratum.
ALL pediatric patients have been considered 
in subgroups defined according to the risk-
adapted polychemotherapeutic protocols they 
were treated with (Table 2). Furthermore, they 
have been also been analyzed by subgroups 
defined according to the early (steroid prephase) 
in vivo response (Table 3). This major subdivision 
has been introduced in order to reach more 
informative results for ALL patients carrying 
detailed features. Since we are referring to a large 
cohort of patients, the defined subgroups still 
remain large in size.
n Statistical ana lysis
The influence of the GST genotypes on hazard 
of relapse was evaluated. The ana lysis takes into 
account the different sampling probabilities by 
risk group (standard, medium and high) and 
status by April 2008 (relapse or no relapse), with 
a median follow‑up of 4 years [28]. In practice, 
each genotyped individual is considered to 
represent the similar nongenotyped individuals 
in the same strata of the whole cohort. This is 
performed using weights equal to the inverse of 
the probability to be sampled. For example, the 
56 genotyped children in the standard‑risk group 
(Table 1) who did not relapse are weighted by the 
inverse of the sampling fraction (by 1/0.115) so 
that they contribute to statistical ana lysis for the 
487 patients not relapsed in the standard risk 
group. Similarly, each of the 22 relapsed children 
genotyped in the standard‑risk group are 
weighted (by 1/0.786) to represent all relapsed 
children in the same risk group. These weights 
were used in the evaluation of the distribution 
of GST‑M1 and GST‑T1 deletions within the 
ALL cohort by the adjusted c2 statistics [28], 
as well as in estimating the relapse cumulative 
incidence by Kaplan–Meier estimator, censoring 
toxic deaths. The comparison was based on the 
Wald test in a Cox model with genotype deletion 
as covariate. The weighted Cox model for two‑
phase design was applied to evaluate the effect 
of deletion on hazard of relapse, adjusting for 
risk group, age and gender. A secondary ana lysis 
evaluated the effect of deletion on the in vivo 
response to the prednisone prephase by means 
of a weighted logistic model, adjusted by age 
group and gender. Two‑sided p‑values <0.05 
were defined as statistically significant. Analyses 
were performed with the survey package of the 
software R [28].
Genetic ana lysis
DNA of the patients was provided by the 
AIEOP Biobank (Clinical and Experimental 
Hematology, Department of Paediatrics, 
University of Padua, Italy). Patients’ DNA 
for genotyping ana lysis was extracted from 
immature blasts of bone marrow aspirates at 
diagnosis or, when not available, at relapse by 
use of a commercial kit (Qiagen, Milan, Italy) 
according to the manufacturer’s protocol. To rule 
out the possibility that genetic mutations were 
acquired upon blasts proliferation, genotyping 
ana lyses were performed on matched bone 
marrow DNA (tumoral, AIEOP Biobank) and 
DNA extracted from peripheral blood of the 
patient in remission, any time it was possible. 
Genotypes were identical between samples of 
the same individual.
Genotype ana lysis for both GST‑M1 
and GST‑T1 stratifies individuals into two 
genetic categories, one being homozygous or 
heterozygous (norm) and the other having a 
homozygous deletion (null). Genotyping was 
performed by multiplex PCR as previously 
described [30]. Only samples in which the 
b‑globin band (used as an internal quality 
control of successful PCR reaction) was clearly 
detected were accepted. To avoid false null 
results due to failure in primer annealing, patient 
samples were mass-amplified (at least 20 at once) 
and randomly replicated. Overall, deletion 
frequencies were those expected for Caucasians.
Results
Ta bl e 4 summarizes the polymorphism 
distribution among the 614 patients, with 304 
null GST‑M1 (51.4%) and 107 null GST‑T1 
(16.3%) patients. Cumulative incidence of 
relapse, estimated with proper weighting to 
account for study design, is reported in Figure 1 for 
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both GST isoforms. The incidence of relapse was 
similar for patients with and without GST‑M1 
deletion (5 years cumulative incidence ± standard 
error: 16.1% ± 1.9 vs 19.1% ± 2.2, respectively; 
p = 0.25; Figure 1a). Table 5 reports the results of 
the Cox model adjusted by risk group, age and 
sex. Subjects with deleted GST‑M1 had hazard 
ratio (HR) of 0.82 with respect to nondeleted 
subjects (p = 0.21; 95% CI: 0.61–1.12). In 
univariate ana lysis, the deletion of GST‑T1 was 
associated with a higher incidence of relapse 
(p = 0.05; Figure 1b). This association loses 
statistical significance when evaluated adjusting 
by risk group, sex and age in the Cox model 
Table 2. Impact of glutathione S‑transferase genotypes (analyzed singly or in 
combination) on the hazard of relapse in acute lymphoblastic leukemia patients 
stratified by risk group. 
GST genotype TOT Relapses 
(n)
Weighted 
5‑year 
cumulative 
incidence of 
relapse (%)
SE Hazard ratio 
(95% CI)
p‑value
Standard risk (75 patients)
GST‑M1 Norm 36 9 4.3 1.7 1 (–) –
Null 39 12 7.4 2.3 1.85 (0.51–6.67) 0.350
GST‑T1 Norm 64 16 4.8 1.2 1 (–) –
Null 11 5 18.0 12.3 4.62 (1.04–20.6) 0.045*
GST‑M1/
GST‑T1
Norm/norm 34 9 4.5 1.8 1 (–) –
Null/norm 30 7 4.9 2.0 1.08 (0.30–3.85) –
Norm/null 2 0 25.7 8.9 –† –
Null/null 9 5 18.0 12.3 4.78 (0.99–23.05) NA‡
Medium risk (340 patients)
GST‑M1 Norm 163 75 21.3 3.2 1 (–) –
Null 177 72 17.0 2.5 0.84 (0.56–1.26) 0.400
GST‑T1 Norm 281 122 18.6 1.9 1 (–) –
Null 59 25 21.0 5.9 1.16 (0.68–1.99) 0.580
GST‑M1/
GST‑T1
Norm/norm 139 64 20.7 3.4 1 (–) –
Null/norm 142 58 16.6 2.7 0.85 (0.54–1.32) –
Norm/null 24 11 25.8 12.3 1.26 (0.56–2.82) –
Null/null 35 14 18.1 6.6 0.96 (0.46–1.97) 0.847§
High risk (188 patients)
GST‑M1 Norm 105 47 35.4 6.6 1 (–) –
Null 83 31 29.0 6.4 0.62 (0.36–1.06) 0.080
GST‑T1 Norm 149 59 30.6 4.6 1 (–) –
Null 37 18 41.0 14.1 1.39 (0.76–2.55) 0.290
GST‑M1/
GST‑T1
Norm/norm 82 36 34.4 7.4 1 (–) –
Null/norm 67 23 25.9 6.5 0.56 (0.30–1.03) –
Norm/null 21 10 38.3 17.0 1.15 (0.52–2.54) –
Null/null 16 8 42.8 22.4 1.00 (0.42–2.36) 0.463§
Analysis by weighed Cox model. Hazard ratio adjusted by sex and age class.
*p < 0.05. 
†Because of the small number of patients and relapses in GST-M1/GST-T1 norm–null and null–null subjects, they were 
pooled together. 
‡No interaction term was assessed because of small number of patients and relapses in GST-M1/GST-T1 norm–null and 
null–null subjects, which were pooled together.  
§p‑value for genotype interaction. 
 NA: Not assessed; SE: Standard error; TOT: Total.
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(p = 0.14; HR: 1.34, 95% CI: 0.90–2.00). 
To assess whether the combination of the two 
deletions had an increased risk of relapse, we 
included an interaction term in the Cox model. 
Results were not statistically significant (overall 
p = 0.64; Table 5 & Figure 1C).
Another test for interaction was applied 
in the Cox model to assess the effect of each 
polymorphism within subgroups defined by 
risk stratification (Table 2) and in vivo prednisone 
response (Table 3). Although none of these 
interaction tests reached statistical significance, 
explorative ana lysis in Table 2 shows that in the 
standard‑risk group, the GST‑T1‑null genotype 
had a significant impact on relapse with more 
than fourfold increase in risk when compared 
with nonmutated subjects (p = 0.045; HR: 4.62; 
95% CI: 1.04–20.6). An adverse role of the 
deletion of GST‑T1 was similarly observed in 
the prednisone good responder (PGR) group 
(p = 0.041; HR: 1.62; 95% CI: 1.02–2.58), 
whereas a protective role of GST‑M1 deletion 
was seen in the prednisone poor responder (PPR) 
group (p = 0.026; HR: 0.45; 95% CI: 0.23–0.91; 
Table 3). Analysis of combined genotypes did not 
provide significant results, possibly due to small 
numbers.
Noticeably, there was no difference in GST‑M1 
and GST‑T1 genotype frequencies or in the 
combined genotype distribution between PGR 
and PPR (logistic model: GST‑M1, p = 0.36; and 
GST‑T1, p = 0.55, data not shown), suggesting 
that GST‑M1 and GST‑T1 are not decisive to 
predict prednisone response itself.
Discussion
Pharmacogenetic studies aimed at investigating 
the impact of homozygous deletions of GST‑M1 
and GST‑T1 on clinical outcome have provided 
conflicting results [19–22,31–33]; small numbers 
of patients, insuff icient statistical power, 
disease complex phenotypes, differences in 
therapeutic procedures and differences in race 
may explain the substantial heterogeneity 
Table 3. Impact of glutathione S‑transferase genotypes (analyzed singly or in 
combination) on relapse in acute lymphoblastic leukemia subjects stratified by 
in vivo prednisone response. 
GST genotype TOT Relapses 
(n)
Weighted 5‑year 
cumulative 
incidence of 
relapse (%)
SE Hazard risk 
(95% CI)
p‑value
Prednisone good responders (473 patients)
GST‑M1 Norm 233 99 17.0 2.2 1 (–) –
Null 240 96 15.3 1.9 0.96 (0.66–1.38) 0.820
GST‑T1 Norm 384 154 14.9 1.3 1 (–) –
Null 88 40 23.4 5.6 1.62 (1.02–2.58) 0.041*
GST‑M1/
GST‑T1
Norm/norm 193 82 16.0 2.3 1 (–) –
Null/norm 191 72 13.7 2.0 0.92 (0.61–1.38) –
Norm/null 39 16 23.5 9.2 1.51 (0.73–3.13) –
Null/null 49 24 22.9 7.1 1.58 (0.86–2.93) 0.778†
Prednisone poor responders (129 patients)
GST‑M1 Norm 70 31 34.2 7.9 1 (–) –
Null 59 19 24.0 6.6 0.45 (0.23–0.91) 0.026*
GST‑T1 Norm 109 42 29.4 5.4 1 (–) –
Null 19 8 31.8 14.5 1.14 (0.51–2.55) 0.750
GST‑M1/
GST‑T1
Norm/norm 61 26 33.2 8.4 1 (–) –
Null/norm 48 16 24.5 7.4 0.48 (0.22–1.05) –
Norm/null 8 5 47.4 31.2 2.06 (0.73–5.82) –
Null/null 11 3 20.0 13.3 0.41 (0.13–1.32) 0.290†
Analysis by weighed Cox model. Hazard ratio adjusted by sex and age. 
*p < 0.05. 
†p‑value for genotype interaction.
Norm: Normal; SE: Standard error; TOT: Total.
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across published results and do not allow a clear 
conclusion to be drawn. In the present study, the 
overall population was large and substantially 
homogenous for ethnicity and risk‑adapted 
chemotherapeutic guidelines. Since the final 
aim of a pharmacogenomic approach is to move 
towards personalized medicine, subset ana‑
lyses have been performed to explore the role 
of GST polymorphisms in specific subjects 
carrying the same features. In fact, ALL itself 
is a heterogeneous disease characterized by 
several immunophenotypes and the therapeutic 
protocols differ in intensity, particularly if we 
consider the high‑ versus standard‑risk arms. The 
effect of potential predictors of response should 
be assessed within the already consolidated risk 
stratification.
Within the whole AIEOP‑BFM ALL 2000 
cohort, 306 children relapsed. Although relapse 
rate increased across risk groups, 214 recurrences 
occurred in patients treated with the lower‑
intensive protocols (28 in the standard‑ and 186 
in the medium‑risk group), indicating that the 
actual reliable risk group classification, based 
mainly on MRD, can still be improved. The 
subsample of ALL subjects to be genotyped 
was selected according to a novel two‑phase 
design. The design and statistical ana lysis of 
two‑phase studies presents several advantages 
over the traditional case–control design, which 
usually has limitations in sample size and in 
matching patients for demographic and clinical 
characteristics [34]. Most importantly, this 
approach is based on already available genetic 
data of a pilot subsample and it takes into account 
the clinical information available on the risk 
group and relapse rate in the whole cohort [28]. 
The selection of the subcohort to be genotyped 
depends on the pilot data available and this may 
be a limitation if such data are sparse or affected by 
selection bias. In this type of design, genotyping 
is not performed when the biospecimens are 
collected, but relies on the quality of stored 
samples. The statistical ana lysis of a two‑phase 
design makes use also of the clinical information 
available on the whole cohort. With proper 
weights, it mimics the full cohort and derives an 
unbiased estimate of the incidence of event and of 
the role of genetic polymorphisms, adjusting by 
relevant factors through multivariate regression 
models [28]. This design is meant for studies 
planned retrospectively with already collected 
biological samples.
Our ana lysis did not correlate GST genotype 
with outcome in the overall population 
(Table 5 & Figure 1), similarly to a previous report 
on large cohort of ALL children treated within 
the AIEOP ALL 1995 study protocol [33]. 
Although similar to the risk‑adapted protocols 
employed, the risk‑assessment criteria used in 
this former AIEOP trial have been overcome 
by the modern prognostic MRD used in the 
AIEOP‑BFM ALL 2000. In our study, GST‑M1 
and GST‑T1 deletions were also not predictive of 
prednisone response. Similarly, in a case–control 
study of 45 PPR and 90 PGR patients, Anderer 
and coworkers did not find any association with 
relapse and initial prednisone response [19].
The demonstrated regulatory role of GST‑M1 
in glucocorticoid‑induced apoptosis in cellular 
models let us suppose that it was meaningful to 
focus on the prednisone response while analyzing 
the role of GST genetic polymorphisms [35]. 
Deletion of GST‑M1 was associated with a better 
clinical outcome within PPR patients (p = 0.026; 
Table 3), but not in all high‑risk patients (p = 0.08; 
Table 4. Frequency of GST‑M1 and GST‑T1 polymorphisms in acute lymphoblastic 
leukemia patients genotyped subgroup and weighted percentage of deletions.
Characteristics Total (n) GST‑M1 GST‑T1
Norm (n) Null, n (%) NA Norm (n) Null, n (%) NA
Total 614 299 304 (51.4) 11 494 107 (16.3) 13
Gender Female 251 125 120 (50.9) 6 213 31 (13.2) 7
Male 363 179 179 (51.8) 5 281 76 (18.6) 6
Age 
(years)
1–5 355 170 178 (55.9) 7 280 68 (18.4) 7
6–9 117 65 49 (37.6) 3 96 16 (9.6) 5
10–17 142 69 72 (50.0) 1 118 23 (15.7) 1
Risk Standard 78 36 39 (50.4) 3 64 11 (11.8) 3
Medium 345 163 177 (53.5) 5 281 59 (17.5) 5
High 191 105 83 (45.0) 3 149 37 (19.2) 5
NA: Not assessed.
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Table 2) according to multivariate ana lysis. 
Similarly, Rocha and coworkers have shown a 
significant correlation between the presence 
of a normal GST‑M1 gene and an increased 
incidence of hematologic relapse in 130 ALL 
patients treated within the high‑risk arm of the 
St. Jude Total XIIIB study protocol, although, 
in this latter study, risk was assessed by different 
criteria [32]. Stanulla and coworkers also found 
that the null genotype for GST‑M1 conferred a 
protective trend on the risk of relapse (p = 0.078) 
in standard‑ and medium‑risk patients with 
B‑cell precursor ALL [20]. PPR represents a 
special subclass of high‑risk patients, treated 
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Figure 1. Weighted cumulative incidence of relapse according to glutathione S‑transferase genotypes. (A) GST‑M1; 
(B) GST‑T1; (C) GST‑M1/GST‑T1. p-value of the Wald test in Cox model with genotype only as covariate. 
M1: GST‑M1; SE: Standard error; T1: GST‑T1.
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with an early aggressive therapeutic approach 
since the very beginning of the therapy (day +8). 
This is equivalent to saying that, among patients 
treated with the most aggressive protocols 
(high‑risk arm), deletion of GST‑M1 confers 
a protective advantage but reduces the risk of 
relapse significantly only in those who respond 
poorly to steroid prephase. More studies are 
needed to clarify if GST‑M1 genotyping could 
be introduced for modulating the front‑line 
treatment in PPR patients, with the GST‑M1 
normal PPR carriers eventually being treated 
with a more aggressive therapeutic regimen and 
undergoing a closer monitoring in comparison 
with GST‑M1 null PPR subjects.
Deletion of GST‑T1 showed a tendency towards 
a worse clinical outcome in patients belonging to 
the PGR group (p = 0.041; Table 3), according to 
multivariate ana lysis. Such association remained 
borderline significant only for PGR patients 
falling within the standard‑risk arm and was lost 
for those in the medium‑risk group (p = 0.045 
and p = 0.58, respectively; Table 2). Although these 
subgroup results are somehow borderline and 
thus need further confirmation, they suggest that 
the adverse effect of the GST‑T1 null genotype 
could be of predictive interest mainly in patients 
with the best prognostic factors. In a case–control 
study comparing relapsed and successfully 
treated patients, Stanulla and coworkers have 
found that GST‑T1 deletion reduced the risk of 
relapse (p = 0.048; OR: 0.36; CI: 0.13–0.99) 
[20]. The conflicting results are most likely 
linked to sample size, patient heterogeneity and, 
eventually, to differences in treatment protocols. 
Indeed, Stanulla and coworkers investigated 64 
matched case–control pairs of standard‑ and 
medium‑risk patients with B‑cell precursor 
ALL [20]. The relative prevalence of GST‑T1 null 
genotype was similar in both our and Stanulla’s 
studies (~15 vs 17.8%, respectively), but our 
analyses have been performed on a larger group 
of subjects (614 vs 128 subjects, respectively), 
treated with the most recent protocol, which used 
a new definition of risk group based on MRD, 
and with all immunophenotypes represented 
(82% B‑cell precursor ALL and 18% T‑cell 
ALL). Stanulla et al. group then assessed the 
role of GST‑T1 three genotypes (zero, one and 
two allele genes) in a larger BFM cohort of 
420 patients treated with the AIEOP‑BFM ALL 
2000, finding a nonsignificant tendency toward 
a better prednisone response in children with 
the null genotype compared with the normal 
homozygous genotype (p = 0.12; RR: 0.41; CI: 
0.14–1.24). Only after a stratified ana lysis using 
those characteristics significantly associated 
with early steroid prephase, a fourfold decrease 
in risk of prednisone poor response arose for 
children with initial blast counts ≥ 3600/µl in 
comparison with the normal (two gene alleles) 
genotype (p = 0.04; RR: 0.25; CI: 0.07–0.92; p 
trend = 0.03) [31].
Since both GST‑M1 and GST‑T1 are phase II 
biotransformation enzymes known for their 
conjugation reaction with GSH, a similar effect on 
relapse would be expected for both null variants. 
On the contrary, our analyses show repeatedly an 
Table 5. Impact of glutathione S‑transferase genotypes (analyzed singly or in 
combination) on the hazard of relapse in acute lymphoblastic leukemia patients. 
GST genotype TOT Relapses 
(n)
Weighted 5‑year 
cumulative incidence 
of relapse, n (%)
SE Hazard ratio 
(95% CI)
p‑value
GST‑M1 Norm 304 131 19.1 2.2 1 (–) –
Null 299 115 16.1 1.9 0.82 (0.61–1.12) 0.212
GST‑T1 Norm 494 197 16.5 1.3 1 (–) –
Null 107 48 24.2 5.3 1.34 (0.90–2.00) 0.144
GST‑M1/
GST‑T1
Norm/
norm
255 109 18.2 2.3 1 (–) –
Null/
norm
239 88 14.8 2.0 0.78 (0.56–1.10) –
Norm/
null
47 21 25.7 8.9 1.24 (0.70–2.20) –
Null/
null
60 27 23.0 6.7 1.16 (0.68–1.99) 0.643†
Overall ana lysis by weighted Cox model. Hazard ratio adjusted by risk group, age class and sex.
†p‑value for genotype interaction.
Norm: Normal; SE: Standard error; TOT: Total.
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opposite trend of the two genotypes. It should 
be noticed that GST‑M1 and GST‑T1 differ in 
amino acid sequence and 3D structure, as well 
as in substrate, organ and cell specificity [36]. 
Particularly, due to a difference in a conserved 
key residue for binding and activation of GSH, 
GST‑T1 has a different catalytic and kinetic 
mechanism for GSH binding and activation 
compared with GST‑M1, and a smaller substrate 
binding domain that is consistent with the 
selectivity of q class GSTs for small xenobiotics 
[37]. Recent findings focused on the regulatory 
role of GSTs in the apoptotic process, particularly 
the case of GST‑M1 and GST‑P1. T‑ALL‑derived 
cell lines have shown that overexpression of 
GST‑M1 inhibits the dexamethasone‑induced 
apoptosis by downregulating the p38‑MAPK 
pathway and the consequent activation of the 
proapoptotic protein Bim [35]. We hypothesize 
that in subjects carrying the GST‑M1 gene 
homozygous deletion, such negative regulation 
does not occur, meaning that that their blasts 
can more easily reach a permissive apoptotic 
environment: the null genotype becomes a more 
favorable condition for patients with otherwise 
adverse clinical condition, such as those who 
respond poorly to glucocorticoids. On the 
contrary, there is no evidence indicating that 
GST‑T1 participates in the apoptotic process. A 
recent PharmGKB summary on GST‑T1 reports 
on correlation between the null genotype and 
antineoplastic‑treatment‑related toxicities 
[38]. These toxicities can cause interruption or 
discontinuation of chemotherapy, enhancing 
the relapse risk and leading to poor prognosis. In 
this report, the impact of GST‑M1 and GST‑T1 
genotypes on toxicities has not been analyzed 
but represents an interesting point for further 
investigation.
The genotyping method adopted in the present 
study does not discriminate between normal/wild‑
type (two alleles) and heterozygous (one allele) 
functional genotypes. A trimodal phenotype 
pattern (slow, intermediate and fast enzymatic 
activity measured in erythrocytes) corresponding 
to genotypes (null, heterozygous and wild‑type 
subjects, respectively) has been described [39–42]. 
No gene dose effect on prednisone response [31] 
or ALL treatment outcome [43] has been found 
so far, when GST‑M1 and GST‑T1 were analyzed 
separately. However, when the latter authors 
considered combined GST‑M1×GST‑T1 gene 
dose effect, they found that poor metabolizers 
(patients with zero or one allele copy, independent 
of the genes considered) showed a better event‑
free survival and lower risk of relapse than good 
metabolizers (carriers of at least two allele copies, 
independent of the genes considered) [43]. In our 
study, combined GST‑M1×GST‑T1 genotypes 
distinguished among more than three total 
allele carriers (norm–norm), one or two total 
allele carriers (norm–null and null–norm) and 
zero allele carriers (null–null). Neither significant 
correlation with outcome (overall p = 0.643; 
Table 5) nor trend proportional to the total allele 
numbers (Figure 1C) have been observed.
In conclusion, our results suggest that GST‑M1 
and GST‑T1 genotypes could be relevant in 
terms of risk of relapse in specific pediatric 
patients’ subsets. If our data are confirmed, 
GST‑M1 and GST‑T1 polymorphisms could 
be considered as additional prognostic factors 
useful to further refine the risk criteria adopted 
in the AIEOP‑BFM ALL 2000 study. These 
results should be considered preliminary 
data and need to be further confirmed in a 
comparable validation cohort before drawing 
f irm conclusions. Contribution of other 
pharmacogenetic determinants should also be 
taken into account.
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Executive summary
Background
  More than 80% of pediatric patients affected by acute lymphoblastic leukemia (ALL) become long-term cancer survivors and healthy 
adults.
  Within risk-adapted polychemotherapeutic groups, there is still wide interpatient variability in clinical response, likely due to patients’ 
genetic features.
  Pediatric ALL treatment success rates can be improved. Patients polymorphisms in genes involved in drug disposition, metabolism and 
mechanisms of action might affect outcome and could be predictor markers of prognosis.
  Deletions in the GST‑M1 and GST‑T1 genes (leading to missing proteins) have been already studied for their influence on ALL outcome 
with controversial results.
Material & methods
  Patients were treated according to the Italian AIEOP-BFM ALL 2000 clinical trial.
  Genotype ana lysis for both GST‑M1 and GST‑T1 stratifies individuals into two genetic categories, one being homozygous or 
heterozygous (norm) and the other having a homozygous deletion (null).
  Study design and statistical ana lysis were based on an innovative approach for pharmacogenetic retrospective study. The novel two-
phase design allows a considerable gain in precision of the estimate of genotype effect on relapse because it introduces sampling 
fractions optimized on the basis of a previous correlation between genotypes and outcome in a pilot study on the same AIEOP-BFM 
ALL 2000 whole cohort.
Results
  No significant association was found in the whole cohort.
  GST‑M1 deletion was associated with better clinical outcome within prednisone poor-responder patients (p = 0.026; hazard ratio 
[HR]: 0.45; 95% CI: 0.23–0.91).
  GST‑T1 deletion was associated with worse outcome in the standard-risk group (p = 0.045; HR: 4.62; 95% CI: 1.04–20.6) and within 
prednisone good responders (p = 0.041; HR: 1.62; 95% CI: 1.02–2.58).
Conclusion
  With 614 patients genotyped, this study is probably one of the largest surveys performed on European pediatric ALL protocols.
  In specific subsets of ALL patients, whose risk has been assessed by already-in-use criteria, assessment of GST‑M1 and GST‑T1 deletions 
could be a candidate genetic tool to improve relapse prediction, probably together with other pharmacogenetic determinants.
  Our results need confirmation in a validation cohort in order to understand their clinical application.
  A deeper knowledge on the regulatory role of glutathione S-transferases on cell cycle is required to finally clarify the contradictory 
results published previously on the clinical effect of glutathione S-transferase variants.
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